Abstract
INTRODUCTION
Following American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) ASCO/CAP 2007 convention, ASCO/CAP came together again in the year 2013 and published a guide. This guide has been commonly introduced into clinical practice.
METHODS
In line with the 2007, and 2013 ASCO/CAP HER2 evaluation recommendations, we reanalyzed 76 cases with breast carcinoma using IHC, and also CISH methods.
RESULTS
A total of 25 cases were IHC 3+ according to both 2007, and 2013 guidelines. Based on 2007 ASCO/CAP HER2 evaluation 23 cases had IHC 2+ scores, while according to 2013 guideline 18 IHC 2+ cases were switched to IHC 3+ group. Based on 2007 ASCO/CAP HER2 evaluations 18 IHC+, and 10 IHC 0 cases were found. Eight IHC 1+ cases were switched to IHC 2+, and 4 cases to IHC 0 groups. Based on 2007 ASCO/CAP HER2 evaluations 25 cases were included in the IHC 3+ group, while according to 2013 ASCO/CAP HER2 evaluations, 43 cases were assessed as IHC3 +.
DISCUSSION AND CONCLUSION
Based on updated evaluation recommendations of ASCO/CAP 2013, some of the IHC2 + cases switched to IHC3 + group which encountered us as the most predominant change.
Keywords: HER2, immunohistochemistry, ASCO-CAP 2007, ASCO-CAP 2013
